Teva Gains Biosimilar Momentum with U.S. FDA Approval of PONLIMSI™ (denosumab-adet) and Dual Filing Acceptance for Biosimilar Candidate to Xolair® (omalizumab)

Teva’s biosimilar, PONLIMSI™, is now FDA-approved across all indications of the reference product, Prolia ® (denosumab), to treat a variety of ...
Portland MercuryOpinion

THE BLACK BYLINE: The Prodigal Elk Statue — And What It Really Means for Portland

Seed to tree, tree to forest; Rain to river, river to sea; Grubs to bees, bees to swarm. From one, many; from many, one; ...
Frontiers

Biological mechanisms underlying tooth movement and tissue remodeling during orthodontic treatment

Orthodontic treatment relies on the biological response of periodontal and alveolar bone tissues to mechanical forces, which induces tooth movement through ...

Re-Teck Addresses the Next Phase of Moore’s Law in the Age of AI

“The rapid refresh cycle of AI infrastructure is creating a new class of secondary market opportunity,” said Linda Li, Chief Strategy Officer at LTG/Re-Teck. “But it also introduces complex challenges ...